Expression Of Heat Shock Protein 90α In Prostate Cancer Patients Before And After Endocrine Therapy

Objective:This study applied the enzyme-linked immunosorbent assay(ELISA)technique to detect the expression of HSP90α in plasma,aiming to investigate whether HSP90α is valuable as a tumor marker to guide the diagnosis of prostate cancer and reflect the effect of endocrine therapy,and to further demonstrate and explore: 1.the expression and diagnostic value of HSP90α in plasma of patients with prostate cancer;2.the relationship between plasma HSP90α and the clinicopathological characteristics of prostate cancer and the efficacy of endocrine therapy was investigated.Methods:From October 2020 to January 2022,30 patients with prostate cancer diagnosed and to be treated with endocrine therapy in the Cancer Hospital of Guizhou Medical University were selected,and 30 normal patients were selected as the control group in the medical examination center of the Cancer Hospital of Guizhou Medical University.The plasma HSP90α levels were quantified by ELISA before and three months after the endocrine therapy in the selected prostate cancer patients at the Laboratory of the Affiliated Cancer Hospital of Guizhou Medical University.Information on HSP90α,PSA and testosterone levels in the control group was collected.Information on PSA and testosterone levels were collected from the prostate cancer group.The data were collated and statistically analyzed.Finally,the subject operating characteristic curve(ROC)was established to determine the optimal threshold value of HSP90α expression in the plasma of patients with prostate cancer.Results:Prostate cancer patients were aged 51-86 years,with a mean of(71.73±8.45)years;tumor TNM stage was T4 in 16 cases,T3 in 8 cases,and T2 in 6 cases;no lymph node metastasis in 7 cases and lymph node metastasis in 23 cases;no distant metastasis in 7 cases and distant metastasis in 23 cases;Gleason score was 10 in 4cases,9 in 6 cases,8 in 9 cases,7 in 8 cases,and 6 in 3 cases The Gleason score was 4out of 10,6 out of 9,9 out of 8,8 out of 7 and 3 out of 6.Healthy volunteers were49-83 years old,with a mean of(71.033±5.86)years,and there was no significant difference between the ages of the two enrolled groups(P>0.05).Plasma HSP90 ɑwas associated with clinicopathological parameters of prostate cancer.Plasma HSP90α,total PSA,and FPSA levels were significantly higher in the prostate cancer group than in the control group,and plasma testosterone levels were higher in the prostate cancer group than in the control group,with statistically significant differences(P<0.05).The Pearson test showed that plasma HSP90α was significantly positively correlated with total PSA and FPSA levels and negatively correlated with testosterone levels(P<0.05).The ROC analysis revealed that the accuracy of plasma HSP90α level for the diagnosis of prostate cancer was 0.8844.The Elisa results showed that after endocrine therapy,plasma HSP90α,total PSA and FPSA levels were significantly higher in the prostate cancer group.,total PSA,FPSA levels and testosterone levels were significantly reduced with statistically significant differences(P<0.05).Conclusions:Plasma heat shock protein 90α can be used as a tumor marker for prostate cancer and correlates with TNM stage and Gleason score of patients with prostate cancer,and its change before and after endocrine therapy can be used as an evaluation index of the effect of endocrine therapy.